Published in Am J Med Sci on April 10, 1984
Non-small cell lung carcinoma presenting as carcinomatous meningitis. Lung India (2010) 0.88
Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry (1991) 0.85
Leptomeningeal carcinomatosis mimicking Creutzfeldt-Jakob disease: clinical features, laboratory tests, MRI images, EEG findings in an autopsy-proven case. Neurol Sci (2012) 0.75
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med (1994) 15.82
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA (1996) 4.13
Comorbidity and functional status are independent in older cancer patients. J Clin Oncol (1998) 4.11
Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol (1998) 2.27
Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med (1980) 2.14
Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest (1982) 1.93
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) (1996) 1.90
Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage (1999) 1.89
Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr (1991) 1.81
Granular cell tumor. Clinical spectrum of the benign and malignant entity. Cancer (1987) 1.58
Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst (1993) 1.50
Current management of breast cancer. Am Fam Physician (1996) 1.47
Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med (1991) 1.46
Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood (1986) 1.43
Effect of beta-globin gene cluster haplotype on the hematological and clinical features of sickle cell anemia. Am J Hematol (1991) 1.43
Overestimation of test effects in clinical judgment. J Cancer Educ (1993) 1.40
Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med (1975) 1.38
Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2000) 1.33
Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J (2007) 1.33
Sexually transmitted diseases in South Africa. Genitourin Med (1996) 1.33
Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer (1993) 1.26
The effect of changing disease risk on clinical reasoning. J Gen Intern Med (1994) 1.23
Mild sickle cell disease. Clinical and laboratory studies. JAMA (1973) 1.21
The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer (1998) 1.19
Validity and reliability of the FACT-G scale for use in the older person with cancer. Am J Clin Oncol (2001) 1.19
Alpha thalassaemia in adults with sickle-cell trait. Br J Haematol (1975) 1.18
Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest (1991) 1.17
Clinical diversity of sickle cell anemia: genetic and cellular modulation of disease severity. Am J Hematol (1983) 1.14
Sickle cell anemia: erythrokinetics, blood volumes, and a study of possible determinants of severity. Am J Hematol (1977) 1.11
Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer (2002) 1.10
Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood (1984) 1.10
Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep (1982) 1.08
Hemoglobin Indianapolis (beta 112[G14] arginine). An unstable beta-chain variant producing the phenotype of severe beta-thalassemia. J Clin Invest (1979) 1.08
Laboratory Diagnosis of sickling hemoglobinopathies. South Med J (1978) 1.05
Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol (1996) 1.03
What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol (2000) 1.02
AIDS and South Africa--towards a comprehensive strategy. Part I. The world-wide experience. S Afr Med J (1988) 1.01
Dominantly inherited beta thalassaemia intermedia caused by a new single nucleotide deletion in exon 2 of the beta globin gene: Hb morgantown (beta91 CTG>CG). J Clin Pathol (2005) 0.99
Microcytosis. Its significance and evaluation. JAMA (1983) 0.97
Molecular basis for nondeletion alpha-thalassemia in American blacks. Alpha 2(116GAG----UAG). J Clin Invest (1987) 0.96
Modulation of erythrocyte-endothelial interactions and the vasocclusive severity of sickling disorders. Blood (1981) 0.96
Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys (1997) 0.96
Metastatic extramammary Paget's disease: dramatic response to combined modality treatment. J Surg Oncol (1988) 0.96
Effect of high concentrations of leukocytes on whole blood viscosity. Blood (1971) 0.93
Beta-thalassemia in southwestern Iran. Hemoglobin (1993) 0.92
Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging (1997) 0.92
A four-base deletion 5' to the A gamma globin gene is a common polymorphism. Blood (1991) 0.91
Hemoglobin Terre Haute arginine beta 106. A posthumous correction to the original structure of hemoglobin Indianapolis. J Biol Chem (1991) 0.91
Breast cancer and aging. Clinical interactions. Hematol Oncol Clin North Am (2000) 0.91
Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma. Cancer (1981) 0.91
Diamond-Blackfan syndrome: evidence for T-cell mediated suppression of erythroid development and a serum blocking factor associated with remission. Br J Haematol (1979) 0.91
Cancer and malnutrition--a critical interaction: a review. Am J Hematol (1985) 0.90
Paraneoplastic eosinophilia. Report of a case with in vitro studies of hemopoiesis. Cancer (1989) 0.89
beta-Thalassemia present in cis to a new beta-chain structural variant, Hb Vicksburg [beta 75 (E19)Leu leads to 0]. Proc Natl Acad Sci U S A (1981) 0.89
Sickle cell anemia in septuagenarians. Blood (1995) 0.88
Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea. Am J Hematol (2000) 0.88
Effects of ascorbic acid on glucose-6-phosphate dehydrogenase-deficient erythrocytes: studies in an animal model. Blood (1977) 0.88
Breast cancer care in old age: what we know, don't know, and do. J Natl Cancer Inst (1993) 0.88
Screening for sickle cell trait: the Veterans Administration National Sickle Cell Program. Am J Hematol (1987) 0.87
Two missense mutations in the beta-globin gene can cause severe beta thalassemia. Hemoglobin Medicine Lake (beta 32[B14]leucine-->glutamine; 98 [FG5] valine-->methionine). J Clin Invest (1995) 0.87
Polymorphisms near a chromosome 6q QTL area are associated with modulation of fetal hemoglobin levels in sickle cell anemia. Cell Mol Biol (Noisy-le-grand) (2004) 0.87
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol (1995) 0.87
The structure of hemoglobin Indianapolis [beta112(G14) arginine]. An unstable variant detectable only by isotopic labeling. J Biol Chem (1979) 0.87
Carcinomatous meningitis: clinical manifestations and management. Int J Clin Pharmacol Ther (1995) 0.86
Chronic granulocytic leukemia. Prolonged survival, muscle infiltration and sea-blue histiocytosis. Am J Med (1973) 0.86
Role of epistatic (modifier) genes in the modulation of the phenotypic diversity of sickle cell anemia. Pediatr Pathol Mol Med (2003) 0.86
Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol (2001) 0.85
Molecular basis for alpha-thalassemia associated with the structural mutant hemoglobin Suan-Dok (alpha 2 109leu----arg) Blood (1990) 0.85
Erythrocyte/endothelial interactions in the pathogenesis of sickle-cell disease: a "real logical" assessment. Blood Cells (1982) 0.85
Influence of HbS levels upon the hematological and clinical characteristics of sickle cell trait. Am J Hematol (1986) 0.84
Beta-thalassemia with exceptionally high hemoglobin A2. Differential expression of the delta-globin gene in the presence of beta-thalassemia. J Lab Clin Med (1982) 0.84
Supplemental vitamin B and progression to AIDS and death in black South African patients infected with HIV. J Acquir Immune Defic Syndr (1999) 0.84
Prevalence of aging population in the Middle East and its implications on cancer incidence and care. Ann Oncol (2013) 0.84
Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol (1994) 0.83
Low-density lipoprotein susceptibility to oxidation and cytotoxicity to endothelium in sickle cell anemia. J Lab Clin Med (1999) 0.83
High proliferation of granulocyte-macrophage progenitors in tumor-bearing mice. Cancer Res (1983) 0.83
Erytrocyte adherence to endothelium as a determinant of vasocclusive severity in sickle cell disease. Trans Assoc Am Physicians (1980) 0.83
Delta beta-thalassemia in an African-American: identification of the deletion endpoints and PCR-based diagnosis. Hemoglobin (1994) 0.83
Circulating micromegakaryocytes signaling blast transformation of chronic myeloid leukaemia. Scand J Haematol (1976) 0.83
Report of a prospective trial--split course versus conventional radiotherapy in the treatment of non small cell lung cancer. Radiat Med (1995) 0.83
Breast irradiation in the older woman: a toxicity study. J Am Geriatr Soc (1994) 0.83
Evaluation of bone scan as a screening work-up in primary and local-regional recurrence of breast cancer. Am J Clin Oncol (1987) 0.83
Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol (1995) 0.83
Herpetic encephalitis with associated cytomegalovirus infection and myoclonus. Lancet (1977) 0.82
The effects of alpha-thalassaemia in HbSC disease. Br J Haematol (1983) 0.81
AIDS and South Africa--towards a comprehensive strategy. Part II. Screening and control. S Afr Med J (1988) 0.81
Hemoglobin Parchman: double crossover within a single human gene. Science (1982) 0.81
[Ascites as an unusual manifestation of chronic granulomatous disease in childhood]. Pediatr Med Chir (1992) 0.81
Development of an HIV clinical and research database for South Africa. Methods Inf Med (1997) 0.81
Regional and temporal variation in oscillatory blood flow in sickle cell disease. Am J Hematol (1988) 0.81
Hb Seal Rock [(alpha 2)142 term-->Glu, codon 142 TAA-->GAA]: an extended alpha chain variant associated with anemia, microcytosis, and alpha-thalassemia-2 (-3.7 Kb). Hemoglobin (1997) 0.80
Severe Hb S-beta+ thalassemia caused by IVS-I splice site mutations. Hemoglobin (1998) 0.80
Early hematopoietic events during tumor growth in mice. J Natl Cancer Inst (1986) 0.80
Clinical and radiologic findings of inner ear involvement in sickle cell disease. AJNR Am J Neuroradiol (2011) 0.80
Evidence of hyposplenism in the presence of splenomegaly. Scand J Haematol (1983) 0.80